UTMB study shows testosterone therapy does not increase aggressive prostate cancer risk

(University of Texas Medical Branch at Galveston) A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive prostate cancer. Further, risk of high-grade prostate cancer did not increase according to the total number of testosterone injections. The study is available in the Journal of Urology.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news

Related Links:

Authors: Yan M, Zhao T, Fu L, Tian R, Li D, Da Y Abstract Long non-coding RNA (lncRNA) prostate cancer-associated transcript 1 (PCAT-1) is a long non-coding RNA involved in the development of various cancer types. Tongue squamous cell carcinoma (TSCC) is the most frequently diagnosed type of oral cancer worldwide. The present study aimed to explore the role of lncRNA PCAT-1 in TSCC, and to provide a preliminary assessment of the downstream pathways involved. The expression levels of lncRNA PCAT-1 in TSCC specimens were first assessed. Subsequently, lncRNA PCAT-1 was knocked down in TSCC cell lines and the resulting...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Transgender children and adolescents may present to care for puberty suppression to prevent undesired and potentially irreversible phenotypic changes that are incongruent with their gender identity. Though histrelin implants have been approved and studied for hormonal axis suppression in medical conditions such as prostate cancer and central precocious puberty, limited data describe its use among children and adolescents with gender dysphoria. Our study aims to characterize the use of the histrelin implant for puberty suppression among transgender youth.
Source: Journal of Pediatric and Adolescent Gynecology - Category: OBGYN Authors: Source Type: research
ConclusionPre-clinical experiments demonstrated promising results for in-situ confirmation of lesion locations in prostates using Raman spectroscopy, both in phantoms and human ex-vivo prostate tissue, which is required for integration in HDR brachytherapy procedures.
Source: International Journal of Computer Assisted Radiology and Surgery - Category: Intensive Care Source Type: research
Publication date: Available online 27 March 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Srinivasa R. Rao, Nasullah K. Alham, Elysia Upton, Stacey McIntyre, Richard J. Bryant, Lucia Cerundolo, Emma Bowes, Stephanie Jones, Molly Browne, Ian Mills, Alastair Lamb, Ian Tomlinson, David Wedge, Lisa Browning, Korsuk Sirinukunwattana, Claire Palles, Freddie C. Hamdy, Jens Rittscher, Clare Verrill
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Publication date: Available online 27 March 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Haisong Tan, Nan Hou, Yanlei Liu, Bin Liu, Wen Cao, Dachao Zheng, Wenzhi Li, Yushan Liu, Bin Xu, Zhong Wang, Daxiang Cui
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
AbstractMultiparametric MRI (mpMRI) of the prostate has been firmly established as a tool in the diagnosis, management, and treatment of prostate cancer. The growth in this field over the past decade has led to increased acceptance and demand for multiparametric prostate MRI across the world. However, with the rising demand for prostate mpMRI, it will become increasingly necessary to train a generation of dedicated prostate imagers to yield a high-quality product.
Source: Abdominal Imaging - Category: Radiology Source Type: research
Conclusions: The recently developed MRI ADC map-based radiomics model was validated in terms of its predictive accuracy of BCR and bRFS after prostatectomy in an external cohort.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 27 March 2020Source: Academic RadiologyAuthor(s): Harrison Kim, John V. Thomas, Jeffrey W. Nix, Jennifer B. Gordetsky, Yufeng Li, Soroush Rais-Bahrami
Source: Academic Radiology - Category: Radiology Source Type: research
Stereotactic ablative radiotherapy (SABR) of oligometastatic disease was superior to observation in men with hormone-sensitive prostate cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Conclusion: Our outcomes support equivalent efficacy and similar risk of adverse effects between apalutamide, enzalutamide, and darolutamide, supporting the use of these antiandrogen agents in high-risk of progression nmCRPC.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
More News: Cancer | Cancer & Oncology | Health | International Medicine & Public Health | Prostate Cancer | Study | Testosterone Injection | Texas University | Urology & Nephrology